Skip to main content
Premium Trial:

Request an Annual Quote

EPO Grants Rosetta Genomics Claims on miR-34a


Rosetta Genomics this week announced that it has received a patent allowance from the European Patent Office for claims related to the use of microRNA-34a for the treatment of p53-negative cancers.

The patent is jointly owned with the Weizmann Institute of Science in Israel, Rosetta said.

According to Rosetta, p53 is a direct transcriptional target of miR-34a and perturbation of the miRNA's expression may contribute to tumorigenesis.

"P53 is a major player in many cancers, and our new findings regarding the role of miR-34a in
exerting its effects has major therapeutic implications,” Weizmann researcher Moshe Oren said in a statement. "One can envision a therapeutic based on mimicking mir-34a in p53-negative cancers, thus overcoming part of the negative effects of missing this important tumor suppressor.”

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.